Clinical Trial: Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Recurrent Or Persistent Small-Volume Epithelial Ovarian Cancer, Primary Peritoneal Serous Cancer, Or Fallopian Tube C

Brief Summary: The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase inhibitor is effective in the treatment of epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancer for patients who have failed first line platinum-based therapy and have a persistent rising CA-125.

Detailed Summary:
Sponsor: Pfizer

Current Primary Outcome: At the completion of Stage 1 of the study, it did not meet the objective response criteria to proceed to Stage 2 of the trial.

Original Primary Outcome:

Current Secondary Outcome: Given the outcome of the primary objective, analysis of secondary objectives were not formalized.

Original Secondary Outcome:

Information By: Pfizer

Dates:
Date Received: December 22, 2003
Date Started: October 2003
Date Completion: September 2004
Last Updated: November 6, 2006
Last Verified: July 2006